Recent

% | $
Quotes you view appear here for quick access.

Roche Holding AG Message Board

lws2000 227 posts  |  Last Activity: 2 hours 52 minutes ago Member since: Nov 21, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Microsoft should move above $60.

  • Reply to

    IMET works on ET, MF MDS and AML.

    by mangymutt Dec 22, 2015 1:37 AM
    lws2000 lws2000 Dec 29, 2015 12:07 AM Flag

    Does anyone believe that IMET does not "work"? Granted that Geron's PPS is too low; that is a separate question that has little to do with science and medicine.

  • Reply to

    trust but verify ??

    by circone Dec 28, 2015 11:53 AM
    lws2000 lws2000 Dec 28, 2015 4:53 PM Flag

    Actually I do believe it, but I have no way to verify it.

  • lws2000 lws2000 Dec 28, 2015 4:49 PM Flag

    Anything is possible. At this late date, with somewhere between 500 and 1000 users in various trials (past and present), the safety factor appears to be very manageable. IMET appears to be unique and effective as a blood cancer treatment with potential in other cancers. As you have repeatedly said, Geron's PPS should be much higher (you blame management), with which I agree (waiting for JNJ to confirm). Whatever problems occurred in the past, JNJ is running the show now.

  • Reply to

    trust but verify ??

    by circone Dec 28, 2015 11:53 AM
    lws2000 lws2000 Dec 28, 2015 3:13 PM Flag

    The problem that I have is believing anyone on this board. I hope the "Ryan Story" is completely true, but I have no way to verify it. We need something official from JNJ.

  • Reply to

    12/22/15 Seeking Alpha GERN Updates.

    by wegbox403 Dec 28, 2015 10:19 AM
    lws2000 lws2000 Dec 28, 2015 2:26 PM Flag

    2016 is the year of IMET and Geron's PPS acceleration. "We now know however the MDS trial is a Phase 2/3 trial with an accelerated approval timeline, which would increase the potential value of Geron based on achieving cash flow at a much earlier date." IMET's full FDA approval is very near.

  • The next chapter for Imetelstat (IMET) is now being written by JNJ/Janssen and Dr. Tefferi as the new data is beginning to make itself available. These new trials are each to last 24 weeks from their date of origin. Some have been underway since Sep. 2015, with over 80 trials planned.

    We need results from JNJ (international) trials confirming Mayo Clinic's MF/IMET successes, and opening some new studies:

    1, JAK and IMET comparisons
    2. Symptom reductions
    3. Remissions and Cures
    4. Blood transfusion frequency
    5. Combination drug studies

    I suspect that JNJ/Janssen already knows, to a large degree, how the MF (Mayo Clinic) follow-ups are going to turn out, since Dr. Tefferi is part and parcel of these new trials. JNJ, being very conservative (medically and legally), is not going to say anything or do anything that they cannot support and prove 100%. All the evidence (most recently the NEJM and ASH) point to major successes with a transformative medicine (Imetetstat). One day soon, Geron's PPS will free itself from the market manipulators and the non-believers. It is no longer "if", but "when". It could happen tomorrow (FDA advanced approvals), and it could happen early in 2016.

  • Reply to

    IMET works on ET, MF MDS and AML.

    by mangymutt Dec 22, 2015 1:37 AM
    lws2000 lws2000 Dec 28, 2015 11:48 AM Flag

    You have to be right. Mayo Clinic, NEJM, JNJ and ASH are 100% reliable sources of information.

  • FireEye Inc.

    Cyber-attacks continue to grab headlines as hacker groups bypass critical government and corporate network security and firewalls to steal private information. Detecting and terminating cyber-attacks continues to be a major problem for corporations, governments and individuals. FireEye Inc. (NASDAQ: FEYE) is able to monitor and track possible cyber threats across all aspects of a business. Its Central Management System smartly detects and blocks incoming attacks, while its Threat Analysis Platform and Forensic Analysis Platform allow for FireEye security analysts and forensic analysts to analyze across an entire enterprise to properly detain attacks so the attacks can be manually destroyed by forensic teams. FireEye does not have a P/E ratio or a forward P/E ratio, but the company has approximately $1.2 billion in cash and short-term investments as of September 2015. The stock has struggled a bit in 2015; it is down almost 30% year to date due in part to an increase in expenses. Overall, FireEye has a strong product in an industry that continues to see strong demand.

  • Reply to

    IMET works on ET, MF MDS and AML.

    by mangymutt Dec 22, 2015 1:37 AM
    lws2000 lws2000 Dec 22, 2015 7:36 PM Flag

    We need results from JNJ (international) trials confirming Mayo Clinic's MF/IMET successes, and opening some new studies:

    1, JAK and IMET comparisons
    2. Symptom reductions
    3. Remissions and Cures
    4. Blood transfusion frequency
    5. Combination drug studies

    I suspect that JNJ/Janssen already knows, to a large degree, how the MF (Mayo Clinic) follow-ups are going to turn out, since Dr. Tefferi is part and parcel of these new trials. JNJ, being very conservative (medically and legally), is not going to say anything or do anything that they cannot support and prove 100%. All the evidence (most recently the NEJM and ASH) point to major successes with a transformative medicine (Imetetstat). One day soon, Geron's PPS will free itself from the market manipulators and the non-believers. It is no longer "if", but "when". It could happen tomorrow (FDA advanced approvals), and it could happen early in 2016.

  • lws2000 lws2000 Dec 22, 2015 5:17 PM Flag

    The FDA must know the significance of all of this.

  • Reply to

    IMET works on ET, MF MDS and AML.

    by mangymutt Dec 22, 2015 1:37 AM
    lws2000 lws2000 Dec 22, 2015 5:16 PM Flag

    It does appear that the FDA must also know and understand the significance of this.

  • We need results from JNJ (international) trials confirming Mayo Clinic's MF/IMET successes, and opening some new studies:

    1, JAK and IMET comparisons
    2. Symptom reductions
    3. Remissions and Cures
    4. Blood transfusion frequency
    5. Combination drug studies

    I suspect that JNJ/Janssen already knows, to a large degree, how the MF (Mayo Clinic) follow-ups are going to turn out, since Dr. Tefferi is part and parcel of these new trials. JNJ, being very conservative (medically and legally), is not going to say anything or do anything that they cannot support and prove 100%. All the evidence (most recently the NEJM and ASH) point to major successes with a transformative medicine (Imetetstat). One day soon, Geron's PPS will free itself from the market manipulators and the non-believers. It is no longer "if", but "when". It could happen tomorrow (FDA advanced approvals), and it could happen early in 2016.

  • lws2000 lws2000 Dec 22, 2015 2:21 PM Flag

    We need results from JNJ (international) trials confirming Mayo Clinic's MF/IMET successes, and opening some new studies:

    1, JAK and IMET comparisons
    2. Symptom reductions
    3. Remissions and Cures
    4. Blood transfusion frequency
    5, Combination drug studies

  • lws2000 lws2000 Dec 21, 2015 6:40 PM Flag

    Mayo Clinic, JNJ/Janssen, NEJM, ASH, peer-reviews also do not lie. Of course that is all science.

  • Reply to

    Oil Export Bill PASSED!!!

    by future_is_fiber Dec 18, 2015 1:24 PM
    lws2000 lws2000 Dec 21, 2015 7:12 AM Flag

    This is oil and natural gas transportation. The demand has not gone down.

  • Reply to

    IMET "never to see the light of day"

    by lws2000 Dec 20, 2015 12:23 PM
    lws2000 lws2000 Dec 21, 2015 12:01 AM Flag

    JNJ, IMET and the FDA: "Blowing in the Wind".

  • The next chapter in IMET's future (and Geron's PPS) is currently being written by JNJ exclusively. Everything depends on the results from IMET's "international exposure", and how those results compare with Mayo Clinic's (Dr. Tefferi's) early successes in their MF trials. The NEJM articles and the ASH conference are positive indicators. Geron will rise or collapse based upon JNJ's fledgling trials. There is every reason to be hopeful, but the fat-lady (JNJ) still has not sung.

    There are agreements between JNJ and Geron that are probably sealed (as some have suggested). JNJ, having been around the block many times with numerous drugs (now FDA approved), no doubt has IMET tied-up as much as legally possible. Geron, as a company, is completely beholden to JNJ, and that is good, since Geron was completely out of their league with a "transformative medicine", that others (companies, hedge funds,) wished "never to see the light of day". IMET is real and JNJ will bring out its full potential.

  • Reply to

    JNJ, NEJM and Mayo Clinic factors

    by lws2000 Dec 18, 2015 2:58 PM
    lws2000 lws2000 Dec 19, 2015 8:54 AM Flag

    The next chapter in IMET's future (and Geron's PPS) is currently being written by JNJ exclusively. Everything depends on the results from IMET's "international exposure", and how those results compare with Mayo Clinic's (Dr. Tefferi's) early successes in their MF trials. The NEJM articles and the ASH conference are positive indicators. Geron rises or collapses based upon JNJ's fledgling trials. There is every reason to be hopeful, but the fat-lady (JNJ) still has not sung.

  • Reply to

    Question for this Message Board GERN

    by buckeyekid1_1 Dec 17, 2015 5:50 AM
    lws2000 lws2000 Dec 18, 2015 8:07 PM Flag

    1.35% of outstanding shares.

RHHBY
31.14-0.11(-0.35%)Feb 9 3:59 PMEST